Overview:
As per the Cleveland Clinic, primary Raynaud’s syndrome affects around 5% to 10% of the general population. This phenomenon is predominantly observed among the female population aged 15 to 30 years. Secondary Raynaud’s syndrome is comparatively more prevalent as its occurrence is associated with the presence of autoimmune diseases. Raynaud’s disease occurs in 90% to 95% of scleroderma patients, 85% of patients with mixed connective tissue disease, 40% of systemic lupus erythematous patients, and 40% of patients with the antisynthetase syndrome. The growing prevalence of autoimmune disease thus increases the occurrence of Raynaud’s syndrome, contributing to the overall growth of this market.
According to the National Institute of Health (NIH), 23.5 million Americans have reported having at least one autoimmune disease. The NIH also reported that the direct healthcare costs associated with autoimmune diseases account for around $100 million. According to a review article published by McFarlane IM et al. (2018) (McFarlane IM, Bhamra MS, Kreps A, Iqbal S, Al-Ani F, et al. (2018) Gastrointestinal Manifestations of Systemic Sclerosis), Rheumatology (Sunnyvale) 8: 235 (doi:10.4172/2161-1149.1000235), the prevalence of scleroderma among the U.S. population accounts for 276 persons per million, and incidence rates account for 20 new cases per million each year. The growing prevalence of scleroderma thus contributes to the overall growth of the Raynaud’s disease therapeutic market.
So far, there are no FDA-approved treatment options for Raynaud’s disease. Calcium channel blockers, vasodilators, and alpha-blockers are prescribed to relieve symptoms. The requirement for a target-based therapy remains a major unmet need in this market, thus creating market opportunities for existing and emerging industrial players. The pipeline molecules BAY63-2521 (Riociguat) by Bayer AG and RayVa (Alprostadil) by Apricus Biosciences, Inc. are being developed for Raynaud’s disease treatment, ensuring potential market growth during the forecast period from 2018 to 2026.
The Raynaud’s disease therapeutics market comprises a vast market outreach across the globe. North America accounted for the major market share owing to the growing prevalence of autoimmune conditions leading to Raynaud’s disease, rising research activities, and increased healthcare expenditure. Asia Pacific is also a potential market owing to its developing healthcare infrastructure, rising awareness about healthcare, and growing Raynaud’s disease prevalence.
The global Raynaud’s Disease Therapeutic Market is segmented as follows:
By Drug Class
- Calcium channel blockers
- Nifedipine
- Amlodipine
- Felodipine
- Alpha-blockers
- Prazosin
- Doxazosin
- Vasodilators
- Losartan
- Fluoxetine
- Pipeline molecules
- BAY63-2521 (Riociguat)
- Raya (Alprostadil)
By Geography
- North America
- United States
- Canada
Europe
- United Kingdom
- Germany
- Rest of Europe
Asia Pacific
- Japan
- China
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- rest of Latin America
Middle East and Africa
- GCC
- Rest of the Middle East and Africa
The global Raynaud’s disease therapeutic market comprises industry leaders, namely, Apricus Biosciences, Inc., Bayer AG, Allergan plc., Covis Pharmaceuticals, Inc., GlaxoSmithKline plc., Zydus Pharma USA, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and others.
This report offers the following:
- A thorough study of the global Raynaud’s disease therapeutics market
- Market analysis for the period from 2016 to 2026, with 2016 as the historical year and 2017 as the base year
- The CAGR for the period from 2018 to 2026 with respect to the entire market and each segment considered has been incorporated in this report.
- A qualitative analysis of the pipeline molecule
- Qualitative information about market dynamic factors such as market drivers, challenges, and opportunities
- An elaborative study on the competitive landscape and the profiling of the key industry leaders
